Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-EST vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of moderate-to-severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis,Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Atrophic vaginitis,Kraurosis vulvae
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
12-18 hours (terminal elimination half-life); clinical context: dosed once daily, steady-state achieved in 5-7 days.
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Renal elimination (90-95%) as glucuronide and sulfate conjugates; fecal (5-10%) via biliary excretion.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
50-80% bound to albumin and sex hormone-binding globulin (SHBG); binding to SHBG is approx. 30-50%.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
1-2 L/kg; clinical meaning: extensive distribution into tissues, including fat and reproductive organs.
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral: 40-60% due to first-pass metabolism; transdermal: approximately 10-20% systemic availability (not primary route).
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min): use with caution due to potential accumulation of conjugated estrogens.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: contraindicated due to impaired estrogen metabolism.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Not indicated for use in pediatric patients.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Initiate at lowest effective dose (0.625 mg orally once daily) and titrate cautiously due to increased risk of thromboembolic events and endometrial cancer.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. They should not be used during pregnancy. There is an increased risk of cardiovascular events (e.g., stroke, myocardial infarction) and breast cancer with estrogen-alone therapy.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Cardiovascular disorders (thrombophlebitis, thromboembolism), malignancy (breast, endometrial), gallbladder disease, hypercalcemia, fluid retention, hepatic impairment, hypothyroidism, and hereditary angioedema.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in select cases), known or suspected estrogen-dependent neoplasia, active or history of venous thromboembolism, active or history of arterial thromboembolism, hypersensitivity to estrogens, hepatic impairment or disease, protein C, protein S, or antithrombin deficiency.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Grapefruit juice may increase systemic exposure to esterified estrogens; avoid concurrent consumption. No other significant food interactions are documented.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., cardiovascular, limb defects, VACTERL association) based on epidemiological data. Second and third trimester exposure may cause fetal harm including urogenital tract abnormalities and potential carcinogenic effects. Estrogens are not recommended for use in pregnancy.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Estradiol is excreted in human breast milk at low concentrations. The M/P ratio is approximately 0.2–0.3. It may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period when milk supply is being established. Alternate methods of contraception should be considered.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
ORTHO-EST is contraindicated in pregnancy. No dose adjustment recommendations exist for use during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) theoretically may require dose adjustment if used, but due to teratogenicity, it should not be used. Postpartum, if estrogen therapy is indicated, consider lower doses due to altered metabolism and risk of thromboembolism.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
ORTHO-EST (esterified estrogens) is indicated for moderate to severe vasomotor symptoms due to menopause and for prevention of postmenopausal osteoporosis. It carries a boxed warning for endometrial cancer in women with an intact uterus; co-administration with a progestin is required unless the patient has had a hysterectomy. Risk of venous thromboembolism is increased; avoid in patients with active VTE or history of VTE. Estrogen use may increase risk of breast cancer, especially with prolonged use (>5 years). Do not use in women with undiagnosed abnormal genital bleeding. Monitor for signs of hypercalcemia in patients with metastatic breast cancer or hypoparathyroidism.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Take ORTHO-EST exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you have a uterus, you must also take a progestin to protect against endometrial cancer risk.,Report any unusual vaginal bleeding, breast lumps, or changes in discharge promptly.,Avoid smoking while taking estrogen therapy; smoking increases risk of serious cardiovascular events.,Notify your healthcare provider if you develop symptoms of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,This medication does not prevent pregnancy; use appropriate contraception unless advised otherwise.,Store at room temperature away from moisture and heat.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-EST vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
ORTHO-EST is a Estrogen Replacement that works by Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to regulation of gene transcription and modulation of various physiological processes including reproductive function, bone metabolism, and cardiovascular health.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-EST and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-EST is: 1.25 mg orally once daily for 21 days, followed by 7 days off; or 0.625 mg orally once daily continuously.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-EST and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-EST is classified as Category C. ORTHO-EST (estradiol) is a pregnancy category X drug. Use is contraindicated during pregnancy. First trimester exposure is associated with a risk of congenital anomalies (e.g., car. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.